Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company, is preparing for a clinical trial event by the end of this year.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, which in combination with standard-of-care (SoC) therapeutics is targeting indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.